101. Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations
- Author
-
Martin J. Boeree, Stephen H. Gillespie, Robin J. Svensson, Elin M. Svensson, Rodney Dawson, Rob E. Aarnoutse, Andreas H. Diacon, Ulrika S. H. Simonsson, Mischka Moodley, European Commission, University of St Andrews. School of Medicine, University of St Andrews. Infection and Global Health Division, University of St Andrews. Global Health Implementation Group, University of St Andrews. Gillespie Group, University of St Andrews. Biomedical Sciences Research Complex, and University of St Andrews. Infection Group
- Subjects
0301 basic medicine ,Early bactericidal effect ,Antibiotics ,Infektionsmedicin ,Pharmacology ,RA0421 ,RA0421 Public health. Hygiene. Preventive Medicine ,Immunology and Allergy ,biology ,Time to positivity ,Middle Aged ,Farmakologi och toxikologi ,early bactericidal activity ,Dose–response relationship ,Infectious Diseases ,Rifampin ,medicine.drug ,Adult ,Infectious Medicine ,RM ,Tuberculosis ,Patients ,medicine.drug_class ,030106 microbiology ,NDAS ,Pharmacology and Toxicology ,Mycobacterium tuberculosis ,models ,Young Adult ,03 medical and health sciences ,All institutes and research themes of the Radboud University Medical Center ,SDG 3 - Good Health and Well-being ,Pharmacokinetics ,medicine ,Humans ,Antibiotics, Antitubercular ,Tuberculosis, Pulmonary ,Dose-Response Relationship, Drug ,business.industry ,Sputum ,Models, Theoretical ,bactericidal effect ,medicine.disease ,biology.organism_classification ,RM Therapeutics. Pharmacology ,Clinical trial ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Pharmacodynamics ,business ,Rifampicin - Abstract
This work was supported by the Swedish Research Council (grant 521-2011-3442 to R. J. S. and U. S. H. S.), the Innovative Medicines Initiative Joint Undertaking (award 115337, with contribution from the European Union’s Seventh Framework Programme [FP7/2007–2013] and the European Federation of Pharmaceutical Industries and Associations [in-kind contribution]), the European and Developing Countries Clinical Trials Partnership (awards IP.2007.32011.011, IP.2007.32011.012, and IP.2007.32011.013), the Netherlands-African Partnership for Capacity Development and Clinical Interventions Against Poverty-Related Diseases, and the Bill and Melinda Gates Foundation. Background The currently recommended rifampicin dose (10 mg/kg) for treating tuberculosis is suboptimal. The PanACEA HIGHRIF1 trial evaluated the pharmacokinetics and early bactericidal activity of rifampicin doses of up to 40 mg/kg. Conventional statistical analyses revealed no significant exposure-response relationship. Our objectives were to explore the exposure-response relationship for high-dose rifampicin by using pharmacokinetic-pharmacodynamic modeling and to predict the early bactericidal activity of 50 mg/kg rifampicin. Methods Data included time to Mycobacterium tuberculosis positivity of liquid cultures of sputum specimens from 83 patients with tuberculosis who were treated with 10 mg/kg rifampicin (n = 8; reference arm) or 20, 25, 30, 35, or 40 mg/kg rifampicin (n = 15/arm) for 7 days. We used a semimechanistic time-to-event approach to model the time-to-positivity data. Rifampicin exposure and baseline time to culture positivity were explored as covariates. Results The baseline time to culture positivity was a significant covariate on the predicted initial bacterial load, and rifampicin exposure was a significant covariate on the bacterial kill rate in sputum resulting in increased early bactericidal activity. The 90% prediction interval for the predicted median day 7 increase in time to positivity for 50 mg/kg rifampicin was 7.25–10.3 days. Conclusions A significant exposure-response relationship was found between rifampicin exposure and early bactericidal activity. Clinical trial simulations showed greater early bactericidal activity for 50 mg/kg rifampicin. Postprint
- Published
- 2018
- Full Text
- View/download PDF